Guest Editors
Fiona Blackhall (left)
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, University of Manchester, Manchester, UK.
Caroline Dive (right)
Cancer Research UK Lung Cancer Centre of Excellence, CRUK Manchester Institute, University of Manchester, Manchester, UK.
This focused issue aims to capture the progress that has been made in the past decade to understand the biology and clinical significance of circulating tumour cells (CTCs) in patients with lung cancer. Crucially, understanding cancer evolution in lung cancer and its associated resistance to therapy can only be achieved with repeated sampling and analysis of the cancer. CTCs provide a readily obtained liquid biopsy and offer unprecedented potential to inform on new treatment strategies. Several platforms now exist for CTC isolation, enumeration and analysis.
